for people ages 21-80 (full criteria)
study started
estimated completion
Principal Investigator
Liviu Klein, MD (ucsf)
Photo of Liviu Klein
Liviu Klein



The purpose of the ARTERY Outcomes study is to compare optima-for-blood pressure (optima4BP), a clinical decision support system for hypertension (HTN) treatment optimization to standard of care in patients with essential HTN.

Official Title

ARTERY Outcomes: Tailored Drug Titration Through Artificial Intelligence - an Interventional Study


Nearly 34 million Americans have their blood pressure (BP) uncontrolled. Hypertension (HTN) claims 1000 deaths every day. Despite medication and life-style management, the cost of HTN associated hospitalizations had escalated to $113 billion in 2016, or 15% of all hospital costs, with >135 million Emergency Department (ED) visits.

Uncontrolled HTN for even a few weeks is associated with increased risk for acute cardiovascular (CVD) events [stroke, heart failure (HF), myocardial infarction (MI)] and death. Medication treatment optimization to BP goal reduces the incidence of stroke by 35-40%, HF by up to 64%, and MI by 15-25%.

optima-for-blood pressure [optima4BP] transforms the episodic and reactive nature of uncontrolled HTN pharmacological treatment management into a process that is continuous, proactive, and personalized. The innovation simulates the established clinical reasoning treatment decision process undertaken during a patient's visit.


Hypertension optima4BP


You can join if…

Open to people ages 21-80

  • Two or more blood pressure (BP) readings of ≥ 140/90 mmHg during UCSF primary care or cardiology office visits within the last 12 months
  • Therapy with medications from at least 1 anti-HTN pharmacological agents at the time of the last office visit
  • At least minimally "tech-savvy" defined as Ownership of a compatible smartphone and Ability to access the internet
  • Active Electronic Health Record MyChart account

You CAN'T join if...

  • Home anti-HTN medication therapy doesn't match the electronic health record medication list
  • Anti-HTN medication therapy changed within 30 days prior to enrollment
  • Inability to operate a BP cuff
  • Incompatible smartphone device (Galaxy S5 Android 5.0)
  • Less than minimally "tech-savvy" defined as Inability to use the Internet
  • Non-compliance with medical follow-up (>3 "no shows" in the previous 12 months)
  • Planned coronary revascularization in the next 12 months
  • Myocardial infarction, coronary revascularization, stroke, cardiac or aortic surgery in the previous 90 days
  • GFR < 30 (CKD stage IV/ V)
  • Treating physician rules out the patient due to superseding health management concerns
  • Treating physician rules out the patient due to other concerns


  • University of California San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UC Health

  • Liviu Klein, MD (ucsf)
    My clinical interests are heart failure and cardiac arrhythmias in patients with heart failure. Having advanced training in both heart failure and electrophysiology, I practice an integrated approach in treating patients with heart failure and cardiac arrhythmias. I am also interested in cardiac recovery using electrical (i.e. cardiac resynchronization) and mechanical (i.e.


accepting new patients
Start Date
Completion Date
Optima Integrated Health
Study Type
Last Updated